Tags Archive Navigation
icon
-
Media ReleaseSandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars
-
Media ReleaseSandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines
-
Media ReleaseSandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation
-
Media ReleaseSandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
-
Media Release
Novartis will das Sandoz Geschäft durch eine hundertprozentige Ausgliederung als eigenständiges Unternehmen abspalten
-
StoryCompassionate use: Providing access to much needed treatments
-
Media ReleaseNovartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria
-
Media ReleaseSandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
-
Media ReleaseNovartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off
-
Featured NewsWorld Sight Day 2022: Raising awareness on the importance of eye health
-
Featured NewsNovartis Hematology: Working to help ensure patients are getting the access they need
-
Media ReleaseNovartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments